In 2019, the Phase II clinical trial NeoFIND (NCT03724253) evaluated the tracer [68Ga]Ga-NeoBOMB1 (Figure 6, 7) in 19 patients with advanced GRPR-expressing malignancies, including BC. Here, GRPR is linked to breast cancer.